塞来昔布对H22肝癌组织环氧合酶2及磷脂酶A2抑制作用

目的考察塞来昔布对小鼠H22肝癌细胞移植瘤生长的抑制作用,并探讨其作用机制。方法40只BALB/c小鼠腋下接种H22肝癌细胞,然后随机分为对照组和低、中、高剂量(100、200、400mg/kg)组,于接种后3天灌胃给药,连续用药15天后处死,计算肿瘤的体积和重量;Western blot法检测瘤组织中胞浆磷脂酶A2和环氧合酶2的表达。结果塞来昔布低、中、高剂量治疗组的小鼠平均瘤重均低于对照组,与对照组相比较有显著性差异(P0.05)。塞来昔布治疗组抑瘤率均大于30%,其中高剂量治疗组的抑瘤率大于75%,作用明显。塞来昔布能够明显抑制胞浆磷脂酶A2和环氧合酶2的表达,具有剂量依赖关系。结论塞来昔布对H22肝癌具有抑制作用,其机制可能是通过抑制胞浆磷脂酶A2及环氧合酶2的表达而发挥抗肿瘤的作用,二者在此过程中具有协同效应。

The inhibitory effect of celecoxib on H22 hepatoma and its mechanism

Objective To investigate the inhibitory effect of celecoxib on the growth of transplanted mouse H22 hepatoma in BALB/c mice in wvo and its anticarcinogenic mechanism. Methods Forty BALB/e mice receiving tumor implantation were divided randomly into control group and eelecoxib groups at low, middle, high dosage （100,200,400 mg/kg）.All the groups were garaged continuously with normal saline or celeeoxib on the third day after implantation. The mice were killed on the 15th day, and the volume and weight of the tumor tissues were calculated. The protein expressions of cytosolic phospholipase A2 and cyelooxygenase-2 were examined in the tumor tissues by Western blot analysis. Results The solid tumor volume and weight of treatment groups were lower than those of control group, and there was significant difference among the groups （ P 〈 0.05）. The tumor inhibitory ratios of treatment groups were more than 30%, especially 75% in high dose group. The protein expressions of cytosolic phospholipase A2 and eyelooxygenase-2 in treatment groups were lower than control group in a dose-dependent mariner. Conclusion Celecoxib can inhibit the growth of transplanted H22 hepatoma in dose-dependent manner. The anticarcinogenic effect of celecoxib depends on not only inhibit- ing the expressing of cyclooxygenase-2, but also the synergistic effect of cytosolic phospholipase A2 and cyclooxygenase-2.